March 24, 2026. 40 items curated for clinical relevance.
Above Threshold
Alabama Medical Cannabis Sales Gear for Spring 2026 Launch
Alabama’s medical cannabis dispensaries are preparing to open in spring 2026, establishing the state’s regulated patient access program that clinicians must understand to recommend products safely.
Read more →Cannabis compounds CBD and CBG may help reverse fatty liver disease, study finds
Cannabis cannabinoids CBD and CBG show potential to reverse fatty liver disease, offering clinicians evidence-based alternatives for managing a prevalent metabolic condition in patient populations.
Read more →From Billion-Dollar Hemp Drinks to FDA Cease-and-Desist Letters: The Cannabis Industry’s …
This article examines regulatory enforcement actions against cannabis beverage companies, highlighting the gap between commercial growth and FDA compliance that clinicians must understand when counseling patients.
Read more →New Top Cannabis Regulator Sets Priorities In First Board Meeting
A newly appointed cannabis regulatory official outlined their agenda at an initial board meeting, establishing governance priorities relevant to clinical practice standards and patient care protocols.
Read more →Brazil’s Cannabis Crossroads: New Rules, Old Truths, and the Road Ahead
Brazil’s evolving cannabis regulations, clinical applications, and implementation challenges relevant to healthcare practitioners prescribing or recommending cannabis therapeutically.
Read more →2 Greater Cincinnati breweries file lawsuit over Ohio ban on THC beverages – WLWT
Two Greater Cincinnati breweries are challenging Ohio’s prohibition on THC-infused beverages through legal action, which could affect regulatory frameworks for cannabis product distribution and clinical cannabinoid delivery methods.
Read more →New Ohio law means THC-infused drinks won’t be available on many store shelves – WTVG
Ohio’s new law restricts THC-infused beverage distribution in retail settings, affecting product availability and patient access to alternative consumption methods.
Read more →Lawmakers strike down bill capping THC levels in Oregon’s cannabis edibles – Yahoo
Oregon lawmakers rejected legislation that would have limited THC concentrations in cannabis edibles, maintaining current regulatory standards relevant to clinical dosing considerations.
Read more →Attempt to limit potency of THC in marijuana edibles fails at Oregon Legislature
Oregon legislators failed to pass a bill restricting THC potency in cannabis edibles, leaving clinicians without regulatory guidance on product strength standardization for patient dosing.
Read more →Cannabis Compounds CBD and CBG Slash Liver Fat and Restore Metabolic Health
Recent research demonstrates CBD and CBG reduce hepatic steatosis and improve metabolic markers, providing clinicians evidence-based information for discussing cannabis compounds’ potential metabolic effects with patients.
Read more →Cannabinoid Oral Mucosal Delivery: Approaches to Formulation, Fabrication, and … – PubMed
This article examines formulation and fabrication methods for delivering cannabinoids through oral mucosal routes, relevant for clinicians optimizing bioavailability and therapeutic efficacy of cannabis-based treatments.
Read more →Study: CBD-Dominant Cannabis Products Provide Significant Anxiety Relief – NORML
A study demonstrates that CBD-dominant cannabis products effectively reduce anxiety symptoms, providing clinicians with evidence-based data to guide patient treatment recommendations.
Read more →Clinical Trial: Cannabis Extracts Significantly Reduce Myofascial Pain – NORML
A clinical trial demonstrates cannabis extracts effectively reduce myofascial pain, providing clinicians evidence-based data for treating this common musculoskeletal condition in their patient populations.
Read more →As a Medical Cannabis Patient, I’m Watching This Supreme Court Case Closely
A medical cannabis patient discusses a Supreme Court case with direct implications for clinical cannabis practice, treatment access, and legal protections for healthcare providers and patients.
Read more →The Week in Weed: March 2026 | Seyfarth Shaw LLP – JDSupra
This article covers weekly cannabis regulatory and legal updates from March 2026, providing clinicians with current industry developments relevant to patient care and compliance.
Read more →Marijuana gummies sold in Ohio recalled. Why, where they were sold – The Columbus Dispatch
Marijuana gummies sold in Ohio were recalled, requiring clinicians to alert patients about potential safety risks and verify product sourcing when recommending cannabis products.
Read more →New Group Launches Ahead of Medicare CBD Pilots – Cannabis Wire
A new organization is forming to prepare for Medicare pilot programs testing cannabidiol (CBD) as a treatment, which could establish clinical evidence and insurance coverage pathways for cannabis-based therapeutics.
Read more →Marijuana Status Based Prohibition Tag Archives – Powers Law Firm PA
This resource addresses marijuana’s legal classification and prohibition status, providing clinicians with essential regulatory information for understanding jurisdictional compliance and patient counseling requirements.
Read more →Louisiana lawmaker files bill to legalize recreational marijuana through licensed dispensaries
A Louisiana legislator proposed legalizing recreational marijuana sales through regulated dispensaries, which could expand patient access and create clinical implications for healthcare providers monitoring cannabis use.
Read more →Mom’s homemade medical cannabis recipe now being sold at Georgia dispensaries
A Georgia mother’s homemade medical cannabis formulation has been commercialized and is now available through licensed dispensaries, demonstrating patient-developed protocols entering the legal retail market.
Read more →Ohio THC drink ban draws lawsuit from Cincinnati breweries
Ohio’s THC beverage ban is legally challenged by breweries, affecting cannabis clinician understanding of state regulatory frameworks and product availability for patient recommendations.
Read more →Israeli researchers find cannabis compounds could lead to 1st drug for fatty liver disease
Israeli researchers identified cannabis compounds as potential therapeutic agents for fatty liver disease, representing the first pharmacological approach to treating this prevalent condition.
Read more →Virginia adult-use sales bills pass both chambers, head to conference committee! – Blog
Virginia’s adult-use cannabis sales legislation passed both legislative chambers and now requires conference committee reconciliation, establishing regulatory framework clinicians must understand for patient care and legal compliance.
Read more →Study highlights pros, cons of medical marijuana as its future in Tennessee remains unknown
A Tennessee study examines medical marijuana’s therapeutic benefits and drawbacks as regulatory status remains uncertain, informing clinical practice considerations in that state.
Read more →2026 Utah legislature on cannabis, psychedelics and kratom – Fox 13
The 2026 Utah legislature addresses cannabis, psychedelics, and kratom policy—relevant to clinicians managing patient access, legal prescribing frameworks, and emerging therapeutic substances in their jurisdiction.
Read more →Oregon Bill To Ban Marijuana Edibles With More Than 10 Milligrams Of THC Fails
Oregon’s proposed legislation to limit THC content in cannabis edibles to 10mg per serving failed, leaving current dosing regulations unchanged and affecting clinical recommendations for patient dosing.
Read more →Georgia bill could limit probable cause for smell of marijuana, cannabis, or hemp – YouTube
Georgia legislation would restrict police use of marijuana smell as probable cause for searches, potentially affecting legal distinctions between cannabis, hemp, and illicit substances in clinical and law enforcement contexts.
Read more →Study reveals cannabis compounds reduce threat of fatty liver disease | Health
Cannabis compounds show potential in reducing fatty liver disease risk, relevant for clinicians evaluating therapeutic applications and patient safety profiles during treatment planning.
Read more →Prescription Cannabidiol CBD Oil Market to Hit US$ 190.9 Billion by 2032 at 23.48% CAGR
The prescription CBD market is projected to reach $190.9 billion by 2032 with 23.48% annual growth, indicating significant expansion in clinical cannabinoid therapeutics and market opportunities for medical practitioners.
Read more →I don’t see the article content provided—only the title “TPS Cannabis News – StratCann” and an empty summary field. Please share the article text so I can write an accurate one-sentence clinical summary.
Read more →InMed Pharmaceuticals Shifts Focus to Therapeutic Programs, Ends BayMedica’s Non …
InMed Pharmaceuticals discontinued its non-core operations at BayMedica, refocusing resources on therapeutic drug development programs relevant to clinical cannabis applications.
Read more →Cannabis Extracts Significantly Reduce Myofascial Pain | Trending – Labroots
This article reports research findings on cannabis extracts’ efficacy for myofascial pain treatment, providing clinicians evidence-based information for patient treatment considerations.
Read more →Pediatricians warn about cannabis use disorder, kids’ easy access to the drug – YouTube
Pediatricians highlight cannabis use disorder in children and concerning accessibility issues, which informs clinical understanding of youth risk factors and treatment needs.
Read more →West Virginia House Passes Bill To Allocate Medical Marijuana Revenue, With Some …
West Virginia legislation allocates medical marijuana tax revenue, addressing funding mechanisms for the state’s cannabis program and affecting clinician practice infrastructure.
Read more →The science behind roadside THC testing and diving into SGI’s zero-tolerance policy – Global News
This article examines THC roadside testing methods and Saskatchewan Government Insurance’s zero-tolerance driving policy, relevant to clinicians counseling patients on impairment detection and legal driving restrictions.
Read more →Mom’s homemade medical cannabis recipe now being sold at Georgia dispensaries
A Georgia mother’s homemade medical cannabis formulation has commercialized through state dispensaries, offering clinicians insight into patient-developed dosing protocols and real-world therapeutic applications.
Read more →‘Pot for Potholes Act’ aims to legalize marijuana in Tennessee and distribute taxes to repair …
Tennessee legislation proposes marijuana legalization with tax revenue allocated to road infrastructure repair, relevant to clinicians tracking state policy changes affecting patient access and medical cannabis programs.
Read more →Digest-Level Clinical Commentary
The convergence of emerging hepatoprotective evidence for CBD and CBG alongside expanding state-level medical access programs suggests we’re entering a phase where cannabis medicine practitioners must develop more sophisticated diagnostic frameworks to match patients with cannabinoid profiles rather than simply recommending whole-plant products. The persistent regulatory fragmentation across jurisdictions and ongoing battles over potency standards underscore that our clinical guidance will remain constrained by policy rather than optimized by pharmacology, requiring us to stay current with both the science and the patchwork of local restrictions affecting our patients’ options. These developments collectively point toward a near-term need for better clinical training in cannabinoid pharmacokinetics and delivery methods, particularly as oral mucosal formulations and evidence-based dosing strategies become more relevant to our practice than they have been in the past.
The digest reflects a bifurcated cannabis landscape in which medical applications are gaining incremental scientific support through controlled research on isolated cannabinoids like CBD and CBG, particularly for metabolic and pain-related conditions, while the commercial sector continues to expand with minimal regulatory consistency across jurisdictions. Regulatory bodies appear to be struggling with fundamental questions about product potency, distribution channels, and labeling standards as cannabis markets mature, with states taking divergent approaches to THC concentration limits and beverage classifications. The tension between evidence-based medical claims and the broader commercialization of cannabis products suggests that clinical practice will increasingly need to distinguish between compounds with emerging research support and the heterogeneous products reaching consumers in largely unregulated markets.
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
FAQ
This News item was assembled from structured source metadata and pipeline scoring.
Have thoughts on this? Share it:
